Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast and cardiometabolic effects in psoriatic arthritis
NL-OMON19880Recruiting
- Sponsor
- Reade, outpatient rheumatology clinic
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of apremilast in psoriatic arthritis (PsA), sponsored by Reade, outpatient rheumatology clinic. Primary endpoint: Body composition by whole-body DXA. Started Jan 2017; status: recruiting.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON19880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON19880.